» Articles » PMID: 30587150

Breast Cancer Primary Tumor ER Expression Pattern Predicts Its Expression Concordance in Matched Synchronous Lymph Node Metastases

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2018 Dec 28
PMID 30587150
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Estrogen receptor (ER) expression is important for treatment selection and prognostication of breast cancer patients. Although the metastases are the main targets of endocrine therapy, ER status is often based on the primary tumor. However, ER expression in breast cancer primary lesion may not match with its synchronous metastatic lesions in some cases. In this study, we analyzed ER expression concordance between breast cancer primary tumor and metastatic lesions.

Methods: Paraffin blocks of 100 primary breast invasive ductal carcinoma cases with axillary lymph node metastases were collected. Five tissue cores were punched out from individual primary breast cancer, and one tissue core from each lymph node metastases to assemble tissue microarrays for ER staining. Samples were then scored as 0, 1+, 2+, and 3+ according to the number and intensity of ER stained tumor cells.

Results: For cases with ER 3+ (strong expression) in all cores of primary lesions (n = 38), ER expression in metastatic lymph node was found in 94.7% of the patients. 91.0% of the metastatic lymph nodes were ER positive, and 84.3% of them to be 3+. Among the 46 cases of ER negative expression in all cores of primary lesions, 39 of them had all the metastatic nodes being ER negative, and ER negative nodes were seen in 95.7% of the metastases. As for 16 cases of ER inconsistent expression in primary lesions, 4 cases showed negative ER expression in all metastatic nodes, 2 cases displayed diffuse consistent ER 3+ expression, and 10 cases displayed variant ER expression.

Conclusions: The findings suggest that ER expression concordance between breast cancer primary lesion and its matched metastatic lesions could be estimated by primary tumor ER expression pattern.

Citing Articles

Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry.

Van Alsten S, Zipple I, Calhoun B, Troester M Cancer Causes Control. 2024; .

PMID: 39702817 DOI: 10.1007/s10552-024-01944-7.


Leveraging preclinical models of metastatic breast cancer.

Pedroza D, Gao Y, Zhang X, Rosen J Biochim Biophys Acta Rev Cancer. 2024; 1879(5):189163.

PMID: 39084494 PMC: 11390310. DOI: 10.1016/j.bbcan.2024.189163.


Emerging role of pioneer transcription factors in targeted ERα positive breast cancer.

Pavithran H, Kumavath R Explor Target Antitumor Ther. 2022; 2(1):26-35.

PMID: 36046086 PMC: 9400756. DOI: 10.37349/etat.2021.00031.

References
1.
Falck A, Ferno M, Bendahl P, Ryden L . Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?. World J Surg. 2010; 34(7):1434-41. DOI: 10.1007/s00268-010-0499-z. View

2.
Thompson A, Jordan L, Quinlan P, Anderson E, Skene A, Dewar J . Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010; 12(6):R92. PMC: 3046433. DOI: 10.1186/bcr2771. View

3.
Sofi G, Sofi J, Nadeem R, Shiekh R, Khan F, Sofi A . Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev. 2012; 13(10):5047-52. DOI: 10.7314/apjcp.2012.13.10.5047. View

4.
Yi M, Huo L, Koenig K, Mittendorf E, Meric-Bernstam F, Kuerer H . Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014; 25(5):1004-11. PMC: 3999801. DOI: 10.1093/annonc/mdu053. View

5.
Ataseven B, Gologan D, Gunesch A, Kehl V, Hoegel B, Beer M . HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics. Breast Care (Basel). 2014; 7(6):465-70. PMC: 3971811. DOI: 10.1159/000345467. View